A securities fraud class action lawsuit has been filed against Zoetis Inc. on behalf of investors who purchased or acquired Zoetis securities between January 14, 2025 and May 6, 2026. The lawsuit, filed in the United States District Court for the Southern District of New York, alleges that the company made materially false and misleading statements and failed to disclose that prescription growth for Librela was weakening, Simparica Trio was losing market share to a lower-priced competitor, and dermatological products Apoquel and Cytopoint were also losing market share. On May 7, 2026, Zoetis reported first quarter 2026 financial results showing a significant decline in its Companion Animal business, causing the stock price to fall 21.5%. Investors have until July 27, 2026 to seek appointment as lead plaintiff in the class action.
Zoetis Inclawsuit alleges weakening prescription growth for Librela and market share losses for Simparica Trio, Apoquel, and Cytopoint, leading to a 21.5% stock drop
ServiceNow Inc